Scleroderma is a umbrella term for a group of autoimmune diseases resulting in changes in blood vessels, skin, muscles, and other organs. The symptoms of Scleroderma include thickened and stiff skin, lethargy, and poor blood flow to extremities of the limbs such as fingers and toes on exposure to cold. Scleroderma can also result in deposition of calcium deposits, Raynaud's syndrome, and esophageal problems.
Scleroderma Drug Market contains market size and forecasts of Scleroderma Drug in Global, including the following market information:
- Global Scleroderma Drug Market Revenue, 2017-2022, 2023-2028, ($ millions)
- Global top five companies in 2021 (%)
The global Scleroderma Drug market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Anti-inflammatory Agents Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Scleroderma Drug include Cumberland Pharmaceuticals, Gilead Sciences, Pfizer, Sanofi, Boehringer Ingelheim, Corbus Pharmaceuticals, Actelion Pharmaceuticals, Bayer and Cytori Therapeutics. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Scleroderma Drug companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Scleroderma Drug Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Scleroderma Drug Market Segment Percentages, by Type, 2021 (%)
- Anti-inflammatory Agents
- Immunosuppressive Agents
- Anti-fibrotic Agents
Global Scleroderma Drug Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Scleroderma Drug Market Segment Percentages, by Application, 2021 (%)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Global Scleroderma Drug Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Scleroderma Drug Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Scleroderma Drug revenues in global market, 2017-2022 (estimated), ($ millions)
- Key companies Scleroderma Drug revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Cumberland Pharmaceuticals
- Gilead Sciences
- Pfizer
- Sanofi
- Boehringer Ingelheim
- Corbus Pharmaceuticals
- Actelion Pharmaceuticals
- Bayer
- Cytori Therapeutics
Industry Market Size
